Lowers the risk of cardiovascular death and hospitalization for heart failure. Sold as Entresto, Entresto Sprinkle. Every FDA application for this active ingredient: 2 branded and 16 generic.
As of Nov 15, 2026, FDA lists 18 applications for Sacubitril; Valsartan (sold as Entresto, Entresto Sprinkle), first approved Jul 7, 2015, with 3 new uses approved and 0 published complete response letters.
| Entresto | Part D | $3.93B | -2% | 826,563 |
| Sacubitril-Valsartan | Part D | $195M | New | 464,229 |
| Entresto Sprinkle | Part D | $1.8M | +1144% | 674 |
| Sacubitril/Valsartan vs Standard Treatment for Preventing Atrial Fibrillation Recurrence After Catheter Ablation in Persistent Atrial Fibrillation Patients With Without HypertensionAtrial Fibrillation (Persistent), Catheter Ablation · Ruijin Hospital | Phase 4 | Not yet recruiting | Nov 2, 2026 |
| Real-world Effectiveness and Safety of Savagen (Sacubitril/Valsartan) in Malaysian HFrEF PatientsHeart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure · Sunway University | — | Not yet recruiting | Oct 30, 2026 |
| Sacubitril/Valsartan Versus Valsartan Alone on Left Atrial Volume Index in Hypertensive PatientsHypertension, Left Ventricular Diastolic Dysfunction · University of Health Sciences Lahore | Not applicable | Not yet recruiting | Oct 2, 2026 |
| [11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection FractionHeart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild · Stony Brook University | Phase 1 | Not yet recruiting | Oct 2, 2026 |
| STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart FailureHeart Failure With Reduced Ejection Fraction, Heart Failure · Kyungsub Song | Phase 4 | Recruiting | Jun 5, 2026 |
| Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot StudyHeart Failure Due to Coronary Artery Disease, Valvular Cardiomyopathy · Kyungsub Song | Phase 4 | Recruiting | May 7, 2026 |
| The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission.Heart Failure · Ziekenhuis Oost-Limburg | Phase 4 | Recruiting | Apr 7, 2026 |
| Manganese-enhanced Magnetic Resonance Imaging in Takotsubo CardiomyopathyTakotsubo Cardiomyopathy · University of Edinburgh | Not applicable | Recruiting | Mar 24, 2026 |
| Jul 7, 2015 | EntrestoNDA 207620 · New molecular entity, new combination | Novartis Pharms Corp | 8 | Marketed |
| Apr 12, 2024 | Entresto SprinkleNDA 218591 · New dosage form | Novartis | 0 | Marketed |
| May 28, 2024 | Sacubitril And ValsartanANDA 213605 | Crystal | 0 | Marketed |
| May 28, 2024 | Sacubitril And ValsartanANDA 213676 | Laurus | 0 | Marketed |
| May 28, 2024 | Sacubitril And ValsartanANDA 213682 | Alembic | 0 | Marketed |
| Jul 9, 2024 | Sacubitril And ValsartanANDA 213719 | Zydus Pharms | 0 | Marketed |
| Aug 22, 2024 | Sacubitril And ValsartanANDA 213604 | Torrent | 0 | Marketed |
| Aug 30, 2024 | Sacubitril And ValsartanANDA 213680 | Biocon Pharma | 0 | Marketed |
| Sep 16, 2024 | Sacubitril And ValsartanANDA 213764 | Alkem Labs Ltd | 0 | Marketed |
| Oct 16, 2024 | Sacubitril And ValsartanANDA 213728 | Macleods Pharms | 0 | Marketed |
| Jan 8, 2025 | Sacubitril And ValsartanANDA 213808 | Lupin | 0 | Marketed |
| Jan 13, 2025 | Sacubitril And ValsartanANDA 213627 | Dr Reddys | 0 | Marketed |
| Jul 16, 2025 | Sacubitril And ValsartanANDA 213611 | Novugen Pharma Sdn | 0 | Marketed |
| Jul 16, 2025 | Sacubitril And ValsartanANDA 213748 | Msn | 0 | Marketed |
| Jul 17, 2025 | Sacubitril And ValsartanANDA 213668 | Hetero Labs Ltd Iii | 0 | Marketed |
| Jan 20, 2026 | Sacubitril And ValsartanANDA 219983 | Somerset Theraps LLC | 0 | Marketed |
| Aug 4, 2026 | Sacubitril And ValsartanANDA 219946 | Umedica | 0 | Marketed |
| Sep 2, 2026 | Sacubitril And ValsartanANDA 213631 | Aurobindo Pharma Ltd | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA